SKP2 Oncogene Is a Direct MYC Target Gene and MYC Down-regulates p27KIP1 through SKP2 in Human Leukemia Cells

被引:78
作者
Bretones, Gabriel
Acosta, Juan C.
Caraballo, Juan M.
Ferrandiz, Nuria
Teresa Gomez-Casares, M. [2 ]
Albajar, Marta [3 ]
Blanco, Rosa
Ruiz, Paula
Hung, Wen-Chun [4 ]
Pilar Albero, M. [5 ]
Perez-Roger, Ignacio [5 ]
Leon, Javier [1 ]
机构
[1] Univ Cantabria, Dept Biol Mol, Inst Biomed & Biotecnol Cantabria,Fac Med, SODERCAN Soc Desarrollo Cantabria,CSIC,IBBTEC, Santander 39011, Spain
[2] Hosp Dr Negrin, Serv Hematol, Las Palmas Gran Canaria 35020, Spain
[3] Hosp Univ Marques de Valdecilla, Serv Hematol, Inst Invest & Formac Marques de Valdecilla, Santander 39009, Spain
[4] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan
[5] Cardenal Herrera CEU Univ, Dept Chem Biochem & Mol Biol, Moncada 46113, Spain
关键词
DEPENDENT KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; C-MYC; CYCLE PROGRESSION; BCR-ABL; NEGATIVE AUTOREGULATION; GENOMIC TARGETS; HUMAN CANCER; DEGRADATION; P27;
D O I
10.1074/jbc.M110.165977
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SKP2 is the ubiquitin ligase subunit that targets p27(KIP1) (p27) for degradation. SKP2 is induced in the G(1)-S transit of the cell cycle, is frequently overexpressed in human cancer, and displays transformation activity in experimental models. Here we show that MYC induces SKP2 expression at the mRNA and protein levels in human myeloid leukemia K562 cells with conditional MYC expression. Importantly, in these systems, induction of MYC did not activate cell proliferation, ruling out SKP2 up-regulation as a consequence of cell cycle entry. MYC-dependent SKP2 expression was also detected in other cell types such as lymphoid, fibroblastic, and epithelial cell lines. MYC induced SKP2 mRNA expression in the absence of protein synthesis and activated the SKP2 promoter in luciferase reporter assays. With chromatin immunoprecipitation assays, MYC was detected bound to a region of human SKP2 gene promoter that includes E-boxes. The K562 cell line derives from human chronic myeloid leukemia. In a cohort of chronic myeloid leukemia bone marrow samples, we found a correlation between MYC and SKP2 mRNA levels. Analysis of cancer expression databases also indicated a correlation between MYC and SKP2 expression in lymphoma. Finally, MYC-induced SKP2 expression resulted in a decrease in p27 protein in K562 cells. Moreover, silencing of SKP2 abrogated the MYC-mediated down-regulation of p27. Our data show that SKP2 is a direct MYC target gene and that MYC-mediated SKP2 induction leads to reduced p27 levels. The results suggest the induction of SKP2 oncogene as a new mechanism for MYC-dependent transformation.
引用
收藏
页码:9815 / 9825
页数:11
相关论文
共 73 条
[1]   Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells by Repressing Erythroid Master Genes without Reversing p27-Mediated Cell Cycle Arrest [J].
Acosta, Juan C. ;
Ferrandiz, Nuria ;
Bretones, Gabriel ;
Torrano, Veronica ;
Blanco, Rosa ;
Richard, Carlos ;
O'Connell, Brenda ;
Sedivy, John ;
Dolores Delgado, M. ;
Leon, Javier .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (24) :7286-7295
[2]   Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease [J].
Agarwal, Anupriya ;
Bumm, Thomas G. P. ;
Corbin, Arnie S. ;
O'Hare, Thomas ;
Loriaux, Marc ;
VanDyke, Jonathan ;
Willis, Stephanie G. ;
Deininger, Jutta ;
Nakayama, Keiichi I. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2008, 112 (05) :1960-1970
[3]   BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27 Kip1 degradation and proliferation of chronic myelogenous leukemia cells [J].
Andreu, EJ ;
Lledó, E ;
Poch, E ;
Ivorra, C ;
Albero, MP ;
Martínez-Climent, JA ;
Montiel-Duarte, C ;
Rifón, J ;
Pérez-Calvo, J ;
Arbona, C ;
Prósper, F ;
Pérez-Roger, I .
CANCER RESEARCH, 2005, 65 (08) :3264-3272
[4]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[5]  
Bernard D, 2003, J CLIN INVEST, V112, P1724
[6]   Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 [J].
Bouchard, C ;
Thieke, K ;
Maier, A ;
Saffrich, R ;
Hanley-Hyde, J ;
Ansorge, W ;
Reed, S ;
Sicinski, P ;
Bartek, J ;
Eilers, M .
EMBO JOURNAL, 1999, 18 (19) :5321-5333
[7]   Novel c-MYC target genes mediate differential effects on cell proliferation and migration [J].
Cappellen, David ;
Schlange, Thomas ;
Bauer, Matthieu ;
Maurer, Francisca ;
Hynes, Nancy E. .
EMBO REPORTS, 2007, 8 (01) :70-76
[8]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[9]   c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells [J].
Ceballos, E ;
Delgado, MD ;
Gutierrez, P ;
Richard, C ;
Müller, D ;
Eilers, M ;
Ehinger, M ;
Gullberg, U ;
León, J .
ONCOGENE, 2000, 19 (18) :2194-2204
[10]   Reciprocal control of forkhead box O 3a and c-myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels [J].
Chandramohan, V ;
Jeay, S ;
Pianetti, S ;
Sonenshein, GE .
JOURNAL OF IMMUNOLOGY, 2004, 172 (09) :5522-5527